Pfizer taps Marina Maher to promote drug for migraines

NEW YORK: Pfizer has named Marina Maher Communications as its PR agency of record for its migraine-treating prescription drug Relpax.

NEW YORK: Pfizer has named Marina Maher Communications as its PR agency of record for its migraine-treating prescription drug Relpax.

Agency president Marina Maher declined to disclose how much the account is worth.

The agency said that Relpax has been shown in clinical trials to provide relief of migraine headaches and all of the symptoms associated with it, such as nausea and sensitivity to light and sound.

Another major drug account that the agency currently works on is GlaxoSmithKline's Flonase. Maher said that one difference between the two drugs' PR is that Flonase is targeted to both men and women, while Relpax will be focused more on women. According to the National Headache Foundation, women are three times more likely than men to have migraine headaches.

Maher said that her agency, which is strong on consumer PR, is benefiting from the trend of drug companies looking more to that expertise. "Part of our heritage is in beauty products. [We're] very good at marketing to that community and forming a bond. There's no reason why pharma [companies] can't do the same."

The firm has recently brought aboard three people focusing on the healthcare/pharmaceutical space and is actively looking to hire a practice leader, Maher said.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.